CrossAssetDataThe Company File
···
NTRA

Natera, Inc.

Natera, Inc. is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Austin, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2.3 billion and a loss of $208 million (its filed statements).

Usage business Services-Medical Laboratories Austin, TX filings since 2014 9 of 9 filed
Ask the desk about NTRA → Compare NTRA with FTRE → Price chart on TradingView ↗ Full EDGAR file ↗ Watch NTRA →

Sector peers: FTREGHGRALRDNT

6.6/10headline grade
vs its business-model standard
5.7/10past 6.6/10present 7.5/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.6 out of ten, 9 of 9 metrics filed: past 5.7 out of ten, present 6.6 out of ten, future 7.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2017. 78th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.2 out of ten. +30.3% a year over 10 filed years; profitable in 0 of 10. 52nd percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 3.5 out of ten. Share count grew 11.6% a year. 0% of cash flow returned. Insiders: 494 sales, 0 purchases. 35th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.1 out of ten. ROE -12%: lost 12¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar. 51st percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.7 out of ten. top 23% of 23 in its family; net margin -9%. 77th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 6.6 out of ten. top 34% of 17 in its family for leadership; chief executive since 2019. 66th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 6.9 out of ten. top 31% of 23 in its family for room to expand. 69th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 8.8 out of ten. top 12% of 23 in its family for growth drivers. 88th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.1 out of ten. top 39% of 20 in its family for expectations against reality. 61st percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 2014. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Product 100%, Licensing and Other under 1%. By geography: United States 98%, Europe, Middle East, India, and Africa 1%, Americas, excluding U.S. under 1%, Asia Pacific and Other under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-27).

Who runs it

Chapman, Steven Leonard (CEO AND PRESIDENT); Rabinowitz, Matthew (EXECUTIVE CHAIRMAN); Moshkevich, Solomon (PRESIDENT, CLINICALDIAGNOSTICS); Fesko, John (PRESIDENT, CHIEF BUS. OFFICER); Brophy, Michael Burkes (CHIEF FINANCIAL OFFICER); Rosenman, Herm (Chief Financial Officer); Rabinowitz, Daniel (SEC. AND CHIEF LEGAL OFFICER); Sheena, Jonathan (CO-FOUNDER); Chapman, Rowan E (director); Baynes, Roy D. (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.